Transformative Role of Artificial Intelligence in the Pharmaceutical Sector

Balisa Mosisa Ejeta[1], Malay K Das[1*], Sanjoy Das[1], Fetene Fufa Bekere[2], Dubom Tayeng[1]

Abstract

Background: The pharmaceutical sector is a critical component of healthcare, driving innovation in drug discovery, development, and delivery. With the increasing integration of artificial intelligence (AI), digital health technologies, and biotechnology, the industry is transforming rapidly. This review examines the key areas of the pharmaceutical industry and highlights the growing impact of AI in enhancing various processes, from drug discovery to clinical trials. To explore the applications of AI in drug discovery, development, manufacturing, clinical trials, personalized medicine, and regulatory compliance. This review also addresses the challenges, such as data privacy and interoperability, that accompany the adoption of AI in the pharmaceutical sector. Methods: A comprehensive review of existing literature and case studies on the application of AI in pharmaceutical research and operations was conducted. Key areas of focus include AI's role in predictive analytics, target identification, manufacturing, supply chain management, clinical trial optimization, and pharmacovigilance. Results: AI significantly enhances drug discovery by improving target identification, predictive modeling, and high-throughput screening. It optimizes manufacturing through real-time quality control and process automation. In clinical trials, AI facilitates patient recruitment and adaptive trial designs, while in personalized medicine, it enables biomarker discovery and treatment optimization. AI also supports regulatory compliance through automated monitoring and risk assessment. Conclusion: AI is transforming the pharmaceutical sector, making processes more efficient, precise, and tailored to individual patients. However, challenges such as data privacy, ethical considerations, and interoperability must be addressed to fully harness AI's potential. Standardization and collaboration will be essential in driving the next phase of innovation in pharmaceutical development and healthcare delivery.

Keywords: Artificial Intelligence, Drug Discovery, Biopharmaceuticals, Clinical Trials, Regulatory Compliance

Significance | This study determined no significant link between serum Vitamin D levels and COVID-19 mortality, except with LDH.

*Correspondence. Balisa Mosisa Ejeta, Department of Pharmaceutical Sciences, Dibrugarh University, India.
E-mail: balisam@wollegauniversity.edu.et

Editor Noman Hossain, Ph.D., And accepted by the Editorial Board September 11, 2024 (received for review June 17, 2024)

Introduction

The pharmaceutical sector plays a crucial role in healthcare by driving advancements in medical science and improving global well-being. It encompasses several key areas, including research and development (R&D), where companies invest heavily in discovering new drugs. Manufacturing follows strict quality standards to ensure safe commercial production. Regulatory affairs manage compliance with the regulations needed for product approvals, while marketing and sales target healthcare professionals and consumers. Additionally, distribution and supply chain management ensure efficient access to medications. Clinical trials are also conducted to evaluate the safety and efficacy of drugs, and the growing role of biotechnology has expanded the sector to

Author Affiliation.
[1] Department of Pharmaceutical Sciences, Dibrugarh University, India
[2] Adama Science and Technology University, India

Please Cite This:
Balisa Mosisa Ejeta, Malay K Das, Sanjoy Das, Fetene Fufa Bekere, Dubom Tayeng (2024). "Transformative Role of Artificial Intelligence in the Pharmaceutical Sector", Journal of Angiotherapy, 8(9),1-7,9933

include biopharmaceuticals, such as vaccines and gene therapies. Furthermore, the production of generics and biosimila represents an essential aspect of this industry (Pharmaceutical Research and Manufacturers of America [PhRMA], 2022; DiMasi, Grabowski, & Hansen, 2016; U.S. Food and Drug Administration [FDA], 2022; International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use [ICH], 2022; Khan, Shah, Ahmad, & Akram, 2017; World Health Organization [WHO], 2019; ICH, 1996; Mak, Saunders, & Jett, 2016; FDA, 2020). The pharmaceutical sector is undergoing a significant paradigm shift driven by technological innovations, scientific breakthroughs, and an increasing emphasis on patient-centric approaches. Key advances include precision medicine, which tailors medical treatment to the unique genetic makeup of each patient, made possible by advances in genomics, proteomics, and data analytics (Collins & Varmus, 2015). Digital health technologies, including wearables, telemedicine, and health apps, are reshaping healthcare delivery by enhancing patient monitoring and enabling real-time data-driven decision-making (Hamburg & Collins, 2010; Topol, 2019; Steinhubl, Muse, & Topol, 2015). Artificial intelligence (AI) is revolutionizing drug discovery, with AI-driven technologies like machine learning and deep learning streamlining drug design and clinical trials (Angermueller, Pärnamaa, Parts, & Stegle, 2016; Ching et al., 2018). Regulatory agencies are also adopting innovative approaches, such as adaptive trial designs and the use of real-world evidence, to accelerate drug approval processes (Kaitin & DiMasi, 2011; Mullard, 2021).

Advancements in biopharmaceuticals and gene therapies are providing highly targeted treatment options for various diseases, further expanding the possibilities for personalized medicine (Baum & Akbari, 2020; High & Roncarolo, 2019). Collaborative research models are increasingly embraced, with partnerships between industry, academia, and startups facilitating faster drug discovery through knowledge sharing (Munos, 2009; Chesbrough, 2003). Additionally, patient engagement and real-world evidence are becoming more prominent in informing clinical decisions and improving healthcare outcomes (Berger et al., 2017; Khozin, Blumenthal, & Pazdur, 2020). Finally, the industry is adopting green chemistry principles and sustainable manufacturing practices to reduce its environmental footprint (Anastas & Warner, 1998; Sheldon, 2014).

Application of Artificial Intelligence in Pharmaceutical Sectors

Artificial Intelligence (AI) has emerged as a transformative technology with applications across diverse industries, including the pharmaceutical sector. This field is undergoing a significant shift due to AI's potential to revolutionize drug discovery, development, manufacturing, clinical trials, and healthcare delivery. This review highlights the numerous ways in which AI is enhancing various processes within the pharmaceutical industry.

Application of AI in Drug Discovery and Development

Predictive Analytics and Target Identification AI algorithms, particularly machine learning models, have transformed drug discovery by improving predictive analytics and target identification. These algorithms analyze vast datasets, expediting early stages of drug development by identifying patterns and predicting potential drug candidates (Xu et al., 2019). AI models, such as machine learning and deep learning, leverage data from genomics, proteomics, chemical structures, and clinical trials to identify drug candidates, assess safety, and estimate effectiveness based on historical data. By predicting compound interactions, toxicity, and pharmacokinetics, AI enables researchers to prioritize drug candidates for further development (Aliper et al., 2016).

Additionally, AI streamlines target identification by analyzing biological data and comprehending disease mechanisms. Natural language processing (NLP) extracts valuable insights from scientific literature, aiding in target identification. AI-driven methods, such as network analysis and knowledge graph construction, integrate diverse data sources to reveal promising therapeutic targets (Ching et al., 2018; Li et al., 2018). AI also excels in integrating multi-omics data, providing a comprehensive understanding of disease pathways and enhancing the accuracy of target identification (Wang et al., 2020; Xiong et al., 2018). Moreover, deep learning models, like neural networks, prioritize drug targets by assessing intricate relationships between molecular features and disease pathways, facilitating therapeutic intervention (Zhang et al., 2019; Gawehn et al., 2016).

Drug Design and Formulation

AI plays a crucial role in drug design and formulation by increasing efficiency in the development of new drugs. AI accelerates drug design through predictive modeling of molecular interactions, optimizing chemical structures, and identifying potential drug candidates. Machine learning models analyze vast chemical and biological datasets to forecast the pharmacological properties of compounds. Additionally, generative models aid in de novo design, creating molecules with desired attributes (Stokes et al., 2020; Segler et al., 2018).

In compound optimization, AI algorithms predict bioactivity, toxicity, and pharmacokinetic properties, allowing medicinal chemists to prioritize and modify compounds more effectively. This results in the development of safer and more effective drugs (Xu et al., 2019). AI also assists in creating pharmacophore models, which identify essential structural and chemical features for drug-target interactions, facilitating the design of molecules that align with

biological targets (Chen et al., 2018; Ekins & Clark, 2018; Schneider et al., 2017). Furthermore, AI optimizes the composition and characteristics of drug formulations by predicting factors such as stability, solubility, and bioavailability, ultimately improving drug delivery outcomes (Seo et al., 2019; Manogaran & Lopez, 2017). AI also supports personalized medicine by integrating individual patient data, genetics, and lifestyle factors, tailoring drug formulations to enhance efficacy and minimize adverse effects (Dehghan & Casas, 2019; Gawehn et al., 2016).

High-Throughput Screening and Virtual Trials

High-throughput screening (HTS) is a vital process in drug discovery, involving the rapid testing of large compound libraries to identify potential drug candidates. AI enhances HTS by improving the efficiency, accuracy, and predictive power of this process. AI algorithms analyze chemical structures, biological activities, and other datasets to prioritize compounds for screening. Machine learning models predict which compounds are likely to be active against specific targets, streamlining compound selection (Unterthiner et al., 2014; Lenselink et al., 2017).

AI also predicts the biological activity of compounds, helping identify potential hits with a higher success rate and minimizing false positives, thus improving the efficiency of HTS campaigns (Xiong et al., 2018; Wu et al., 2018). In addition, AI optimizes screening assays by selecting appropriate conditions and readouts, resulting in more robust and informative experiments (Scott & Ochoa, 2016; Dai & Devarajan, 2017). AI also aids in hit triage and lead optimization by analyzing structure-activity relationships and predicting pharmacokinetic properties, ensuring the selection of compounds with desirable characteristics for further development (Wallach & Heifets, 2018; LeCun et al., 2015). Lastly, AI integrates data from chemical databases, literature, and experimental results, providing a comprehensive view that enhances decision-making in hit identification and lead optimization (Durrant & McCammon, 2011; Lo et al., 2018).

Application of AI in Manufacturing and Supply Chain

Quality Control and Process Optimization

Artificial Intelligence (AI) has played a transformative role in the areas of quality control (QC) and process optimization across various industries, including pharmaceuticals. Its contributions ensure product quality, regulatory compliance, and operational efficiency. A key application of AI in this field is automated visual inspection, where AI-driven image recognition and computer vision are employed to enable real-time product inspection. These systems detect defects and inconsistencies, improving both the accuracy and efficiency of QC (Van der Maaten & Hinton, 2008). Another important application is in spectroscopy and analytical techniques, where AI analyzes spectroscopic data in real-time to maintain the quality of raw materials and intermediate products. By utilizing machine learning models to detect patterns and deviations, AI enhances the precision of QC (Shanmugam, Muthukumar, & Palanisamy, 2019).

AI is also pivotal in predictive maintenance, analyzing historical data to predict equipment failures. This allows for proactive maintenance that minimizes downtime and ensures consistent product quality (Wang & Li, 2015). In terms of process optimization and control, AI algorithms adjust manufacturing parameters in real time, reducing variations and enhancing efficiency. AI-enabled closed-loop control systems manage processes adaptively, ensuring operational consistency (Kadam, Jadhav, & Gambhire, 2014). Furthermore, AI helps in maintaining regulatory compliance and documentation by automating the documentation process and analyzing regulatory data, thereby reducing errors and supporting adherence to quality standards (Tang, Davison, & Ekel, 2006).

Supply Chain Management

Artificial Intelligence (AI) is revolutionizing supply chain management by automating processes, optimizing operations, and improving decision-making. One significant application of AI is in demand forecasting, where machine learning is used to analyze historical data and market trends, leading to improved inventory management and fewer stockouts (Garg & Deshmukh, 2006). In inventory management, AI takes into account factors such as demand variability and supplier performance, which helps prevent overstocking and reduces costs (Sarkis, 2003).

Moreover, AI contributes to supplier relationship management by supporting risk assessment and performance monitoring. Natural Language Processing (NLP) is employed to analyze unstructured data, such as contracts, to enhance supplier evaluations (Riquelme & González, 2018). AI also optimizes logistics by improving transportation routes and adjusting delivery schedules in response to real-time changes (Coyle, Bardi, & Langley, 2003). Additionally, AI enables predictive maintenance, which prevents equipment failures and reduces downtime. When integrated with blockchain technology, AI enhances supply chain transparency and traceability, ensuring greater accountability and fostering trust (Iansiti & Lakhani, 2017).

Application of AI in Clinical Trials

Patient Recruitment and Eligibility

AI is enhancing patient recruitment and eligibility in clinical trials by automating the identification of suitable participants. AI algorithms analyze electronic health records (EHRs), medical literature, and other healthcare data to identify potential candidates. NLP aids in extracting relevant information more accurately, and AI also helps optimize protocols by aligning trial criteria with patient data using machine learning, ensuring precise eligibility matching (Doshi-Velez & Perlis, 2014). Automated pre-

screening tools reduce manual workload and improve efficiency in identifying eligible participants (Holmes et al., 2012). Furthermore, predictive analytics enhance recruitment by forecasting enrollment rates, allowing trial sponsors to allocate resources effectively based on patient demographics and historical data (Ross et al., 2010). These AI-driven advancements streamline patient recruitment, improve accuracy, and enhance the overall efficiency of clinical research, ultimately accelerating drug development and clinical trial success (Wagholikar et al., 2014).

Real-World Evidence and Adaptive Trial Design

AI is also transforming clinical trial methodologies through real-world evidence (RWE) and adaptive trial designs. AI algorithms analyze data from diverse real-world sources, including EHRs and wearables, providing a broader understanding of patient populations, disease progression, and treatment outcomes (Richesson & Hammond, 2013). AI enables patient stratification and subgroup identification, targeting specific patient profiles for adaptive trials, and predictive analytics help forecast recruitment rates and treatment responses (Sherif, Hassen, & Salem, 2019). This real-time adaptation of trial designs optimizes protocols and enhances trial efficiency (Obermeyer & Emanuel, 2016). AI further improves dynamic randomization by continuously adjusting patient allocation based on ongoing trial data and automates endpoint adjudication to ensure data quality (Pocock & Simon, 1975). Overall, AI's integration of RWE and adaptive trial designs increases trial flexibility, efficiency, and success (Bryant, Fisher, & Gent, 1984).

Application of AI in Personalized Medicine and Treatment Optimization

Biomarker Discovery

AI is revolutionizing biomarker discovery by analyzing complex datasets to identify critical markers for disease diagnosis, prognosis, and treatment. AI integrates multi-omics data, such as genomics and proteomics, to uncover potential disease-associated biomarkers (Cortes & Vapnik, 1995). Machine learning techniques, including support vector machines and deep learning, are employed to recognize patterns in biological data, revealing biomarkers (Guyon & Elisseeff, 2003). Additionally, AI aids in feature selection and dimensionality reduction, simplifying complex data to focus on the most relevant variables (Barabási & Oltvai, 2004). Network analysis reveals biomolecular interactions and pathways linked to disease mechanisms, and NLP accelerates biomarker discovery by mining biomedical literature for pertinent information (Cohen et al., 2005). Transfer learning techniques further enhance biomarker identification, even with limited data, significantly improving the efficiency and accuracy of biomarker discovery (Yosinski et al., 2014).

Treatment Decision Support

AI plays a pivotal role in treatment decision support, enabling healthcare professionals to tailor therapies based on individual patient characteristics. AI supports personalized and effective clinical decision-making by integrating insights from diverse data sources. Key applications include:

Medical Imaging Interpretation: AI aids in interpreting radiology and pathology images, identifying patterns and anomalies that guide treatment decisions (Esteva et al., 2017).

Genomic Data Analysis: AI helps oncologists and geneticists customize therapies based on a patient's genetic profile by analyzing genetic data (Katsila, Patrinos, & Kardamakis, 2017).

Clinical Decision Support Systems (CDSS): AI-driven systems analyze patient data, EHRs, and medical literature to provide evidence-based treatment recommendations (Osheroff et al., 2007).

Natural Language Processing (NLP): AI-powered NLP reviews large amounts of medical literature, assisting clinicians in staying updated with research and incorporating evidence-based practices (Névéol et al., 2014).

Predictive Analytics: AI predicts potential treatment outcomes, helping to select the most effective options based on historical data (Obermeyer & Emanuel, 2016).

Remote Patient Monitoring: AI processes data from wearables to track patient health in real time, enabling timely adjustments to treatment plans (Steinhubl, Muse, & Topol, 2015).

Application of AI in Regulatory Compliance and Pharmacovigilance

Regulatory Intelligence

AI is increasingly utilized in regulatory compliance to monitor, analyze, and interpret evolving laws and standards throughout drug development. AI-powered tools automate the process of monitoring regulatory changes by scanning large volumes of documents, keeping organizations updated on new compliance requirements (Zhang et al., 2018). Natural Language Processing (NLP) simplifies complex regulatory texts, helping to identify key compliance needs (Lippi & Frasconi, 2010). Moreover, AI-driven predictive analytics can forecast regulatory trends based on historical data, allowing companies to proactively adjust their strategies (Obermeyer & Emanuel, 2016). AI also supports risk assessments by evaluating potential compliance risks and monitoring adherence to regulations. In addition, AI automates the generation of regulatory reports, ensuring accuracy and compliance (Grimmer & Stewart, 2013; Chen et al., 2015). These applications enhance organizational efficiency and agility, enabling adaptation to the dynamic regulatory landscape.

Pharmacovigilance and Adverse Event Monitoring

AI is revolutionizing pharmacovigilance by automating the detection of adverse events and improving post-market

surveillance. Machine learning algorithms analyze large datasets, including electronic health records and social media, to detect potential safety signals for adverse events associated with drugs (Aramaki et al., 2010). NLP further aids in extracting information from unstructured data sources like medical literature and social media (Lopes et al., 2017). AI-driven models predict potential adverse events using historical data, improving the speed and accuracy of signal detection (Harpaz et al., 2012). Real-world data from sources such as health records and wearable devices provide a broader view of patient experiences, facilitating early detection of adverse events (Khozin et al., 2017). AI automates the triage and processing of adverse event reports, prioritizing critical cases for faster responses (Wu et al., 2018). By monitoring patient-reported outcomes in real-time via social media, AI significantly enhances pharmacovigilance efforts, contributing to improved patient safety (Sarker et al., 2015).

Challenges and Future Directions

Data Privacy and Ethical Considerations

The integration of AI into the pharmaceutical sector raises significant data privacy and ethical concerns. AI systems often handle sensitive patient data, such as electronic health records and genetic information, necessitating robust data anonymization, encryption, and de-identification techniques to ensure privacy (Fernández-Alemán et al., 2013). Transparency is crucial; patients must be fully informed about AI's role in their healthcare and give explicit consent for data usage (Gostin & Nass, 1997). Furthermore, AI algorithms can inherit biases from historical data, which may lead to unequal treatment outcomes (Beauchamp & Childress, 2019). It is essential to implement measures to mitigate bias and ensure fairness in healthcare delivery (Obermeyer et al., 2019). Additionally, the reliance on AI increases vulnerability to cyber threats, making robust cybersecurity practices a priority. Ownership and control of data, especially when multiple stakeholders are involved, require clear guidelines (Kierkegaard, 2015). Furthermore, the opaque nature of AI systems, often referred to as "black boxes," complicates accountability, highlighting the need for explainability and regular monitoring to maintain trust, accuracy, and ethical integrity (Vayena & Blasimme, 2017).

Interoperability and Standardization Challenges

The lack of standardization in data formats and the limited interoperability between AI systems present major barriers to collaboration and data sharing in the pharmaceutical industry. Pharmaceutical data originates from various sources, including electronic health records, clinical trials, and real-world evidence, but is often stored in heterogeneous formats. This fragmentation complicates seamless integration between AI systems and hampers collaboration (Musen et al., 2015). Moreover, the absence of standardized governance frameworks and data-sharing protocols adds further complexity. Integrating AI into legacy systems presents additional technological and regulatory hurdles (Kleiner & Talwalkar, 2015). Proprietary systems can also lead to vendor lock-in, raising costs and limiting flexibility (Downing et al., 2017). Addressing these challenges through the establishment of common standards and collaborative frameworks is essential to fully realize AI's potential in pharmaceutical research and development (Wiederhold et al., 2012; Harpaz et al., 2012).

Conclusion

The pharmaceutical industry is undergoing a profound transformation fueled by the integration of artificial intelligence (AI), digital health technologies, and sustainable practices. AI accelerates drug discovery by enhancing predictive analytics, target identification, and the development of personalized medicine through data-driven insights and deep learning. It optimizes manufacturing and supply chain operations by improving quality control, process efficiency, and regulatory compliance. In clinical trials, AI streamlines patient recruitment, protocol design, and real-time monitoring, boosting overall efficiency. Personalized medicine benefits from AI's role in biomarker discovery, while regulatory compliance is supported through automated monitoring and risk assessment. Despite challenges like data privacy, ethical concerns, and interoperability barriers, collaboration and standardization are key to realizing AI's full potential in creating more effective, personalized, and sustainable healthcare solutions.

Author contributions

All authors made equal contributions to the study design, statistical analysis, and drafting of the manuscript. The corresponding author, along with the co-authors, reviewed and approved the final version of the article prior to submission to this journal.

Acknowledgment

The authors were grateful to their department.

Competing financial interests

The authors have no conflict of interest.

References

Aliper, A., Plis, S., Artemov, A., Ulloa, A., Mamoshina, P., & Zhavoronkov, A. (2016). Deep learning applications for predicting pharmacological properties of drugs and drug repurposing using transcriptomic data. Molecular Pharmaceutics, 13(7), 2524–2530.

Anastas, P. T., & Warner, J. C. (1998). Green chemistry: Theory and practice. Oxford University Press.

Angermueller, C., Pärnamaa, T., Parts, L., & Stegle, O. (2016). Deep learning for computational biology. Molecular Systems Biology, 12(7), 878.

Aramaki, E., Miura, Y., Tonoike, M., & Ohkuma, T. (2010). Twitter catches the flu: detecting influenza epidemics using Twitter. In Proceedings of the Conference on Empirical Methods in Natural Language Processing (EMNLP) (pp. 1568–1576).

Barabási, A. L., & Oltvai, Z. N. (2004). Network biology: understanding the cell's functional organization. Nature Reviews Genetics, 5(2), 101–113.

Baum, A., & Akbari, O. (2020). Targets for SARS-CoV-2 mRNA vaccination. New England Journal of Medicine, 383(17), 1673-1675.

Beauchamp, T. L., & Childress, J. F. (2019). Principles of Biomedical Ethics. Oxford University Press.

Berger, M. L., Sox, H., Willke, R. J., Brixner, D. L., Eichler, H. G., Goettsch, W., ... & Watkins, J. B. (2017). Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE special task force on real-world evidence in health care decision making. Pharmacoepidemiology and Drug Safety, 26(9), 1033-1039.

Bryant, J., Fisher, L., & Gent, M. (1984). The process of adjudication by committee in the clinical trial of symptomatic versus asymptomatic patients. Controlled Clinical Trials, 5(2), 99–110.

Chen, H., Engkvist, O., Wang, Y., Olivecrona, M., & Blaschke, T. (2018). The rise of deep learning in drug discovery. Drug Discovery Today, 23(6), 1241–1250.

Chen, M., Hao, Y., Hwang, K., Wang, L., & Cho, C. (2015). Machine-to-machine communications: Architectures, standards, and applications. KSII Transactions on Internet and Information Systems, 9(6), 2236–2263.

Chesbrough, H. W. (2003). Open innovation: The new imperative for creating and profiting from technology. Harvard Business Press.

Ching, T., Himmelstein, D. S., Beaulieu-Jones, B. K., Kalinin, A. A., Do, B. T., Way, G. P., ... & Xie, W. (2018). Opportunities and obstacles for deep learning in biology and medicine. Journal of The Royal Society Interface, 15(141), 20170387.

Ching, T., Himmelstein, D. S., Beaulieu-Jones, B. K., Kalinin, A. A., Do, B. T., Way, G. P., et al. (2018). Opportunities and obstacles for deep learning in biology and medicine. Journal of The Royal Society Interface, 15(141), 20170387.

Cohen, A. M., Hersh, W. R., Dubay, C., & Spackman, K. (2005). Using co-occurrence network structure to extract synonymous gene and protein names from MEDLINE abstracts. BMC Bioinformatics, 6(1), 1–14.

Collins, F. S., & Varmus, H. (2015). A new initiative on precision medicine. New England Journal of Medicine, 372(9), 793-795.

Cortes, C., & Vapnik, V. (1995). Support-vector networks. Machine Learning, 20(3), 273–297.

Coyle, J. J., Bardi, E. J., & Langley, C. J. (2003). The management of business logistics: A supply chain perspective. South-Western Cengage Learning.

Dai, Y., & Devarajan, K. (2017). Learnings from a decade of virtual screening in the pharmaceutical industry. Expert Opinion on Drug Discovery, 12(6), 511–522.

Dehghan, A., & Casas, J. P. (2019). Personalised medicine and population health: Breast and ovarian cancer. The EPMA Journal, 10(3), 239–253.

DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016). Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics, 47, 20-33.

Ding, C., & Peng, H. (2005). Minimum redundancy feature selection from microarray gene expression data. Journal of Bioinformatics and Computational Biology, 3(2), 185–205.

Doshi-Velez, F., & Perlis, R. H. (2014). Discovering personal topics in documents: An efficient algorithm and its evaluation. Journal of Machine Learning Research, 15, 751–773.

Downing, N. S., Shah, N. D., Aminawung, J. A., Pease, A. M., Zeitoun, J. D., Krumholz, H. M., & Ross, J. S. (2017). Postmarket safety events among novel therapeutics approved by the US Food and Drug Administration between 2001 and 2010. JAMA, 317(18), 1854–1863.

Durrant, J. D., & McCammon, J. A. (2011). NNScore: A neural-network-based scoring function for the characterization of protein-ligand complexes. Journal of Chemical Information and Modeling, 51(11), 2528–2545.

Ekins, S., & Clark, A. M. (2018). Ligand-based target prediction for small molecules with artificial intelligence. Journal of Chemical Information and Modeling, 58(1), 138–149.

Esteva, A., Kuprel, B., Novoa, R. A., Ko, J., Swetter, S. M., Blau, H. M., & Thrun, S. (2017). Dermatologist-level classification of skin cancer with deep neural networks. Nature, 542(7639), 115–118.

FDA. (2020). Generic drugs. https://www.fda.gov/drugs/generic-drugs

FDA. (2022). Current good manufacturing practice (CGMP) regulations. https://www.fda.gov/drugs/pharmaceutical-quality-resources/current-good-manufacturing-practice-cgmp-regulations

Fernández-Alemán, J. L., Señor, I. C., Lozoya, P. Á. O., & Toval, A. (2013). Security and privacy in electronic health records: a systematic literature review. Journal of Biomedical Informatics, 46(3), 541–562.

Garg, A., & Deshmukh, S. G. (2006). A review of literature and an empirical study of supply chain integration: The Indian perspective. International Journal of Physical Distribution & Logistics Management, 36(9), 757–775.

Gawehn, E., Hiss, J. A., & Schneider, G. (2016). Deep learning in drug discovery. Molecular Informatics, 35(1), 3–14.

Grimmer, J., & Stewart, B. M. (2013). Text as data: The promise and pitfalls of automatic content analysis methods for political texts. Political Analysis, 21(3), 267–297.

Guyon, I., & Elisseeff, A. (2003). An introduction to variable and feature selection. Journal of Machine Learning Research, 3, 1157–1182.

Hamburg, M. A., & Collins, F. S. (2010). The path to personalized medicine. New England Journal of Medicine, 363(4), 301-304.

Harpaz, R., DuMouchel, W., Shah, N. H., Madigan, D., Ryan, P., & Friedman, C. (2012). Novel data-mining methodologies for adverse drug event discovery and analysis. Clinical Pharmacology & Therapeutics, 91(6), 1010–1021.

High, K. A., & Roncarolo, M. G. (2019). Gene therapy. New England Journal of Medicine, 381(5), 455-464.

Holmes, J. H., Elliott, T. E., Brown, J. S., Raebel, M. A., Davidson, A., & Nelson, A. F. (2012). Clinical research data warehouse governance for distributed research networks in the USA: A systematic review of the literature. Journal of the American Medical Informatics Association, 19(2), 149–159.

Iansiti, M., & Lakhani, K. R. (2017). The truth about blockchain. Harvard Business Review, 95(1), 118–127.

ICH. (1996). Guideline for good clinical practice E6(R2). https://ichgcp.net/

ICH. (2022). Regulatory affairs. https://www.ich.org/page/regulatory-affairs

Kadam, R. U., Jadhav, A. R., & Gambhire, M. N. (2014). Quality by design: A holistic approach. International Journal of Research in Pharmacy and Chemistry, 4(3), 614–625.

Kaitin, K. I., & DiMasi, J. A. (2011). Pharmaceutical innovation in the 21st century: New drug approvals in the first decade, 2000–2009. Clinical Pharmacology & Therapeutics, 89(2), 183-188.

Katsila, T., Patrinos, G. P., & Kardamakis, D. (2017). Whole genome sequencing in pharmacogenomics. Frontiers in Pharmacology, 8, 6.

Khan, M. U., Shah, S. A. A., Ahmad, F., & Akram, M. (2017). A comprehensive review of marketing strategies in the pharmaceutical industry. Health Marketing Quarterly, 34(2), 134-146.

Khozin, S., Blumenthal, G. M., & Pazdur, R. (2020). Real-world evidence and clinical trials. New England Journal of Medicine, 382(10), 958-962.

Kierkegaard, P. (2015). Vulnerability, trust, and patient–doctor contracts. Journal of Medicine and Philosophy, 40(3), 244–264.

Kleiner, A., & Talwalkar, A. (2015). A scalable bootstrap for massive data. Journal of the Royal Statistical Society: Series B (Statistical Methodology), 77(2), 233–269.

LeCun, Y., Bengio, Y., & Hinton, G. (2015). Deep learning. Nature, 521(7553), 436–444.

Lenselink, E. B., Ten Dijke, N., Bongers, B., Papadatos, G., Van Vlijmen, H. W. T., & Kowalczyk, W. (2017). Beyond the hype: deep neural networks outperform established methods using a ChEMBL bioactivity benchmark set. Journal of Cheminformatics, 9(1), 45.

Lippi, M., & Frasconi, P. (2010). A survey of web information extraction systems. Data & Knowledge Engineering, 69(3), 259–267.

Lopes, F. M., de Souza, T. P., & de Jesus, V. C. (2017). A systematic review of the use of social media for the dissemination of gray literature. Journal of the Medical Library Association, 105(2), 131–140.

Mak, T. W., Saunders, M. E., & Jett, B. D. (Eds.). (2016). Primer to the immune response (2nd ed.). Academic Press.

Mullard, A. (2021). 2020 FDA drug approvals. Nature Reviews Drug Discovery, 20(2), 85-90.

Munos, B. (2009). Lessons from 60 years of pharmaceutical innovation. Nature Reviews Drug Discovery, 8(12), 959-968.

Musen, M. A., Bean, C. A., Cheung, K. H., Dumontier, M., Durante, K. A., Gevaert, O., ... & Zheng, J. (2015). The center for expanded data annotation and retrieval. Journal of the American Medical Informatics Association, 22(6), 1148–1152.

Névéol, A., Dalianis, H., Velupillai, S., Savova, G., & Zweigenbaum, P. (2014). Clinical natural language processing in languages other than English: opportunities and challenges. Journal of Biomedical Semantics, 5(1), 1–11.

Obermeyer, Z., & Emanuel, E. J. (2016). Predicting the future—big data, machine learning, and clinical medicine. New England Journal of Medicine, 375(13), 1216–1219.

Obermeyer, Z., & Emanuel, E. J. (2016). Predicting the future—big data, machine learning, and clinical medicine. New England Journal of Medicine, 375(13), 1216–1219.

Obermeyer, Z., Powers, B., Vogeli, C., & Mullainathan, S. (2019). Dissecting racial bias in an algorithm used to manage the health of populations. Science, 366(6464), 447–453.

Osheroff, J., Teich, J., Levick, D., Saldana, L., Velasco, F., Sittig, D., & Rogers, K. (2007). Improving outcomes with clinical decision support: An implementer's guide. HIMSS.

PhRMA. (2022). About us. https://www.phrma.org/about

Pocock, S. J., & Simon, R. (1975). Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics, 31(1), 103–115.

Prosperi, M., Min, J. S., Bian, J., & Modave, F. (2019). Big data hurdles in precision medicine and precision public health. BMC Medical Informatics and Decision Making, 19(1), 1–9.

Riquelme, J. C., & González, A. (2018). A review of machine learning for the prognosis of machinery health. Mechanical Systems and Signal Processing, 104, 799–834.

Ross, J., Tu, S., Carini, S., Sim, I., & the Analysis and Design of Informatics. (2010). Analysis of eligibility criteria complexity in clinical trials. AMIA Summits on Translational Science Proceedings, 2010, 46–50.

Sarker, A., Chandrashekar, P., Magge, A., Cai, H., Klein, A., Gonzalez, G., & Scotch, M. (2015). Discovering cohorts of pregnant women from social media for safety surveillance and analysis. Journal of Medical Internet Research, 17(10), e237.

Sarkis, J. (2003). A strategic decision framework for green supply chain management. Journal of Cleaner Production, 11(4), 397–409.

Shanmugam, S., Muthukumar, S., & Palanisamy, P. (2019). An intelligent system for quality control of pharmaceutical tablet using UV spectroscopy and machine learning. Journal of Pharmaceutical Analysis, 9(6), 451–457.

Sheldon, R. A. (2014). Green and sustainable manufacture of chemicals from biomass: State of the art. Green Chemistry, 16(3), 950-963.

Sherif, M. M., Hassen, D. I., & Salem, A. B. (2019). An artificial intelligence technique for predicting the possible risk of medical disease based on electronic health records. Health Information Science and Systems, 7(1), 1–10.

Steinhubl, S. R., Muse, E. D., & Topol, E. J. (2015). Can mobile health technologies transform health care? JAMA, 314(12), 1235–1236.

Steinhubl, S. R., Muse, E. D., & Topol, E. J. (2015). The emerging field of mobile health. Science Translational Medicine, 7(283), 283rv3.

Tang, Y., Davison, M., & Ekel, P. (2006). Data preparation for data mining. Applied Artificial Intelligence, 17(3), 375–381.

Topol, E. (2019). Deep medicine: How artificial intelligence can make healthcare human again. Hachette UK.

Van der Maaten, L., & Hinton, G. (2008). Visualizing high-dimensional data using t-SNE. Journal of Machine Learning Research, 9(Nov), 2579–2605.

Vayena, E., & Blasimme, A. (2017). Biomedical big data: new models of control over access, use and governance. Journal of Bioethical Inquiry, 14(4), 501–513.

Wagholikar, K. B., MacLaughlin, K. L., Laje, P., & Sabb, F. W. (2014). Machine learning-based prediction of clinical trial enrollment. Journal of Biomedical Informatics, 52, 296–307.

Wang, D., & Li, P. (2015). Machinery fault diagnosis and signal processing—a review. Artificial Intelligence Review, 43(1), 83–119.

WHO. (2019). Good distribution practices for pharmaceutical products. https://www.who.int/medicines/areas/quality_safety/quality_assurance

Yosinski, J., Clune, J., Bengio, Y., & Lipson, H. (2014). How transferable are features in deep neural networks? In Advances in Neural Information Processing Systems (pp. 3320–3328).

Zhang, X., Zhang, Y., Liu, Y., Hou, W., & Xu, J. (2018). Regulatory compliance in cloud service provisioning: A survey. IEEE Transactions on Cloud Computing, 6(2), 315–326.